Rating Change
Wedbush analysts reiterated a Outperform rating on Kura Oncology, Inc. (NASDAQ:KURA) on July 28, 2026.
reiterateNASDAQ:KURA
Wedbush Reiterates Outperform Rating on Kura Oncology, Inc. (KURA)
Rating Change Wedbush analysts reiterated a Outperform rating on Kura Oncology, Inc. (NASDAQ:KURA) on July 28, 2026. Market Context Kura Oncology, Inc.
Market Context
Kura Oncology, Inc. operates in the Healthcare sector. The stock currently trades at $9.42 with a market capitalization of $911.1M.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kura Oncology, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Kura Oncology, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 28, 2026 | Wedbush | Outperform | N/A |
| Jun 15, 2026 | Citizens | Market Outperform | N/A |
| Apr 14, 2026 | Lake Street | Buy | N/A |
| Mar 24, 2026 | Mizuho | Outperform | N/A |
| Mar 13, 2026 | UBS | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KURA Stock Page
Frequently Asked Questions
What does a Outperform rating mean for KURA?
A Outperform rating from Wedbush reflects the analyst's outlook on Kura Oncology, Inc. (NASDAQ:KURA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KURA forecast page.